thrv-1268
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Jun 6, 2024 (NCT06507839)
Timeline
Indications
Mechanism of action
- Serine/threonine-protein kinase Sgk1INHIBITOR
SGK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07277582 | Phase 2/Phase 3 (Phase 3) | Jan 31, 2026 | Thryv Therapeutics, Inc. |
| NCT07186946 | Phase 1 | Sep 15, 2025 | Thryv Therapeutics, Inc. |
| NCT06507839 | Phase 1 | Jun 6, 2024 | Thryv Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Thryv Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2024 |
1 organizations
Page 1 / 1